Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
187 results about "Oxyde nitrique" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nitric oxide releasing oxindole prodrugs for anagesic, Anti-inflammatory and disease-modifying use
Nitric oxide releasing oxindole prodrugs are described which are useful in methods of treating or preventing pain, inflammation, fever, or gastrointestinal lesions in a patient in need of such treatment, or of modifying an inflammatory disease or condition by favorably affecting the outcome thereof in said patient, wherein there is administered to said patient a therapeutically effective amount of a compound of Formula (I): and pharmaceutically acceptable salts thereof. In preferred embodiments, X is a covalent bond; RA and RB are both hydrogen; n is the integer 4; Y is -O-; Z is -NO2; RC is a member selected from the group consisting essentially of 5-Cl and 5-F; RD is a member selected from the group consisting essentially of 6-Cl and 6-F; and RE is a member selected from the group consisting essentially of benzyl, 2-furyl, 2-thienyl, 5-chloro-2-thienyl and 5-trifluoromethyl-2-thienyl.
Owner:PFIZER INC +1
Nanocomposite copper-ceria catalysts for low temperature or near-ambient temperature catalysis and methods for making such catalysts
InactiveUS6857431B2Reduce the amount requiredTobacco preparationNon-fibrous pulp additionPtru catalystHydrocotyle bowlesioides
Nanocomposite copper-ceria catalysts are provided, which comprise copper oxide nanoparticles, copper nanoparticles, or a mixture thereof combined with ceria nanoparticles. Methods for making such catalysts are also provided, which involve the steps of (i) combining ceria nanoparticles in an aqueous suspension with copper 2,4-pentanedionate to form a slurry; (ii) heating the slurry formed in step (i) under an inert gas atmosphere or an oxygen-argon atmosphere, at a temperature and for a time sufficient to cause decomposition of the copper 2,4-pentanedionate to form copper nanoparticles and / or copper oxide nanoparticles that are combined with the ceria nanoparticles; and (iii) optionally, subjecting the product formed in step (ii) to a heat treatment process under conditions effective to convert at least some of the copper nanoparticles to copper oxide nanoparticles. The nanocomposite copper-ceria catalysts are useful for low-temperature and near-ambient temperature catalysis, such as the oxidation of carbon monoxide, the reduction of nitric oxide and the conversion of hydrocarbons. The nanocomposite copper-ceria catalysts have a variety of potential applications, for example, in vehicle exhaust emission systems of automobiles and diesel engines, cold starting of automobile engine, fuel cells, lasers, hydrocarbon conversion reactors, air filters for the conversion of carbon monoxide and / or indoor volatile organic compounds, and smoking articles.
Owner:PHILIP MORRIS USA INC
Neuronal pain pathway
ActiveUS20060216339A1High activityImprove the level ofNervous disorderDipeptide ingredientsCyclasePhosphorylation
The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
The invention describes novel nitrosated and / or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and / or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.
Owner:NICOX SA
Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
ActiveUS20100209469A1Rapid hydrolysisHighly controllable hydrolysis profileSuture equipmentsBiocidePolymer scienceDrug release
The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and / or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.
Owner:BEZWADA BIOMEDICAL LLC
Heteroarylacrylamides and their use as pharmaceuticals
The present invention relates to heteroarylacrylamides of the formula I,in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
Owner:SANOFI SA
Differential delivery of nitric oxide
This invention relates to devices and methods for the local, differential delivery of nitric oxide within the body. The devices include devices having at least two differing nitric oxide donor compounds, such as nitric oxide donor compounds having differing half-lives and nitric oxide donor compounds having different release mechanisms. The devices also include devices having at least two chemically distinct compositions to which nitric oxide donor compounds are adsorbed or attached or within which the donor compounds are disposed. The devices are typically used to increase local nitric oxide concentration in the body upon placement of the medical article at a delivery position on or within a patient. The methods of the present invention include a method of treating an atherosclerotic lesion which comprises: exposing the lesion to a first higher concentration of nitric oxide effective to reduce the number of cells within the lesion; and subsequently exposing the lesion to a second lower concentration of nitric oxide effective to inhibit restenosis. The methods of the present invention also include methods for preferentially providing differing nitric oxide donor compounds within different tissues to effect therapy.
Owner:BOSTON SCI SCIMED INC
Cold storage solution for organ and biological tissue preservation
InactiveUS20020064768A1Increase storage spacePotent vasodilatory propertyBiocideTetrapeptide ingredientsNitric oxideBiological activation
Cold storage solutions for the preservation of organs and biological tissues prior to implantation, including a prostaglandin having vasodilatory, membrane stabilizing, platelet aggregation prevention upon reperfusion, and complement activation inhibitory properties, a nitric oxide donor, and a glutathione-forming agent.
Owner:ORGAN RECOVERY SYST
Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
ActiveUS20140017121A1Reduce bacterial adhesionReduces and eliminates bacterial adhesionSilicon organic compoundsPharmaceutical containersNitrosoThiol
Provided according to embodiments of the invention are novel tertiary alkyl thiol compounds and novel tertiary alkyl nitrosothiol compounds. Further provided according to embodiments of the invention are methods of forming a nitric oxide (NO)-releasing xerogel coating that include (a) co-condensing a sol precursor solution comprising at least one backbone alkoxysilane and at least one tertiary thiol alkoxysilane in a solvent to form a sol; (b) coating a substrate with the sol; (c) optionally, drying the sol to form the xerogel coating; and (d) contacting the xerogel coating with a nitrosating agent. Methods of using xerogel coatings are also included.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Nano-Structured Composite Material and Process of Making for Enclosed Space Air Detoxing and Deodoring
ActiveUS20150126357A1Improve efficiencyLower resistanceMolecular sieve catalystsDispersed particle separationNanoporous carbonToxic chemical
The present invention is related to a nano-structured composite material and process of making for air detoxing and deodoring in enclosed spaces to prevent harmful chemicals in the air from damaging human health. The nano-structured composite material consists of nano-porous carbon, zeolites with sub nano-size pores and at least 1 other component chosen from nano-porous rare earth oxides and nano-sized catalysts, and is made into highly efficient configurations with high geometric surface and low resistance air flow channels. The synergetic action of those nano-structured components can effectively remove toxic chemicals including, but not limited to formaldehyde, benzene, toluene, xylene, propene, butadiene, acetone, carbon monoxide, nitric oxide, nitrogen dioxide, sulfur dioxide, hydrogen sulfide, ammonia, alcohols, chlorine, mercaptans, as well as bad odors, such cigarette smoke and bathroom / toilet smells.
Owner:QI XIWANG +1
method and apparatus for controlling a process of injury therapy
ActiveUS20120010683A1Easy to adjustMinor side effectsDiagnostics using lightSurgeryControl signalNitric oxide
The invention provides a method and apparatus for controlling a process of injury therapy. The method comprises the steps of: monitoring (11) a Nitric Oxide level of the injury, generating (12) a controlling signal by comparing the Nitric oxide level with a predefined threshold, and adjusting (13) a dosage of light for the injury therapy according to the controlling signal.
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO−), or as the neutral species, nitric oxide (NO.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and / or treating respiratory disorders.
Owner:ARBOR PHARMA LLC
Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
InactiveUS7138430B2Prevention of platelet aggregation and platelet adhesionAntibacterial agentsBiocideMetaboliteAntioxidant
Owner:NICOX SA
Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
A cosmetic treatment device includes a nitric oxide (NO) eluting polymer, a carrier, and a proton donor enclosed in a container that keeps the proton donor separate from the nitric oxide eluting polymer until the device is used. When the container is opened, proton donor contacts the polymer, causing the elution of nitric oxide from the polymer.
Owner:NAVAN INC
Nitric oxide manipulation of muscle satellite cell activation
InactiveUS6967102B1Change effectEnhance the beneficial effectHalogenated hydrocarbon active ingredientsCompound screeningWhole bodyBiological activation
The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle.
Owner:UNIVERSITY OF MANITOBA
Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and / or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and / or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and / or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.
Owner:NICOX SA
Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
The combination of amlodipine and atorvastatin act to synergistically synthesize NO production. Moreover, the addition of a tertiary compound complements this combination of amlodipine and atorvastatin in NO production.
Owner:MASON R PRESTON
Apparatus for the controlled release of topical nitric oxide
ActiveUS20140296773A1Portability suitableSuitable shelf lifePeptide/protein ingredientsInorganic active ingredientsControl releaseMedicine
A stable delivery system for the therapeutic release and application of nitric oxide to a patient suffering from a cutaneous injury or wound includes a S-nitrosothiol and transition element nanoparticles. The transition metal nanoparticles are selected to react with the S-nitrosothiol to release and diffuse nitric oxide into the injury or wound.
Owner:UNIVERSITY OF WINDSOR
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and / or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and / or oxatriazole-5-imines.
Owner:NICOX SA
Quantum dot/polymer composite nitric oxide fluorescent probe and preparation method thereof
ActiveCN102585417ASensitive detectionEasy to detectFluorescence/phosphorescenceLuminescent compositionsPolymethyl methacrylateGlycerol
The invention relates to a quantum dot / polymer composite nitric oxide fluorescent probe and a preparation method thereof. The fluorescent probe is a powdered solid and is prepared from a quantum dot and methyl methacrylate (MMA) by an in-situ composite method, wherein the quantum dot and MMA polymer are combined though a covalent bond. The preparation method comprises the following steps of: 1) dispersing and dissolving water-soluble cadmium salt in a mixed solution of the MMA and a coupling agent, performing prepolymerization reaction at the temperature of between 70 and 90 DEG C under the action of an initiator under the protection of N2, and stopping reacting when the viscosity of a system is approximate to that of glycerol; 2) adding an aqueous solution of a sulfur source, a selenium source or a tellurium source into the prepolymer system in the step 1) dropwise with violent stirring under the protection of the N2 until the system is quickly discolored, wherein the molar ratio of the sulfur source, the selenium source or the tellurium source to the cadmium salt is 1.1:1-1.4:1; and 3) polymerizing at the temperature of between 50 and 70 DEG C for 10 to 24 hours. The fluorescent probe has the double advantages of the quantum dot and the polymer, is high in stability and is suitable for detecting nitric oxide in a sample to be detected.
Owner:GUANGDONG NANHAI ETETB TECH CO LTD
Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
InactiveUS20070155734A1Unexpected potential for facilitating wound healingImproved profileBiocideSenses disorderDiseaseCyclooxygenase
The invention provides novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions and kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor, and / or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and / or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and / or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and / or preventing renal and / or respiratory toxicity; for treating and / or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
Owner:NICOX SA
Antioxidant and anti-inflammatory activity of compounds and preparations from African nutmeg seeds
The present invention provides methods for reducing the production of nitric oxide, inducible nitric oxide synthase protein and mRNA, and cyclooxygenase-2 protein and mRNA in cells both in vivo and in vitro via the administration of extracts and compounds derived from the seeds of Pycnanthus angolensis Warb. (P. Kombo), commonly known as African nutmeg. These extracts and compounds, namely, kombo butter, kombo butter acid extract, sargaquinoic acid, sargachromenol, and sargahydroquinoic acid, are also useful in the treatment and prevention of a battery of adverse health conditions in human, animal, and avian subjects that are advanced by the production of nitric oxide or its metabolites and / or by the activity of cyclooxygenase-2. Methods for the isolation of kombo butter acid extracts are also provided.
Owner:RUTGERS THE STATE UNIV +1
Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
ActiveUS20190343869A1Enriched delivery capacityImprove compound stabilityAntibacterial agentsOrganic active ingredientsDiseaseControl manner
Disclosed herein are cyclodextrin molecules covalently modified to store and release nitric oxide, as well as methods of making and uses thereof. The covalently modified cyclodextrin molecules may be tailored, in several embodiments, to release nitric oxide in a controlled manner and are useful for reduction and / or eradication of bacteria and for the treatment of disease.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Nitric oxide scavengers
InactiveUS20050256169A1Improved therapeutic compositionWithout inhibiting nitric oxide synthesisBiocideAnimal repellantsScavengerNitric oxide
Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applications, such as to prevent or treat intradialytic hypotension during dialysis.
Owner:BAXTER HEALTHCARE SA +1
Substituted aromatic-ring compounds, process for producing the same, and use
InactiveUS7078540B1Low toxicityTreatment and/or prophylaxis of diseasesOrganic chemistryOrganic compound preparationHydrogen atomHalogen
Owner:TAKEDA PHARMA CO LTD
System and method for recovering methyl nitrite through coal ethylene glycol carbonyl synthesis system
InactiveCN107056582AReduce shortingReduce pollutionOrganic compound preparationHydroxy compound separation/purificationChemical reactionFluid phase
The invention relates to the field of coal ethylene glycol chemical engineering and particularly relates to a system and method for recovering methyl nitrite through a coal ethylene glycol carbonyl synthesis system. According to the method, the main target of effectively recovering a methyl nitrite gas is achieved in the coal ethylene glycol carbonyl synthesis system through the methods of combining air stripping, flash evaporation and nitric acid reduction. The recovery system mainly comprises a front air stripping system for methyl nitrite, a nitric acid reduction system and a rear air stripping system, wherein the front air stripping system is provided with a liquid-phase preheater, a front air stripping tower and a liquid-phase discharge centrifugal pump; the nitric acid reduction system is provided with a liquid-phase feeding preheater and a nitric acid reduction tower; and the rear air stripping system is provided with the flash evaporation tank, the liquid-phase feeding centrifugal pump and the rear air stripping tower. Stable content of nitric oxide and the methyl nitrite in a gas-phase component of the synthesis system is ensured through the method of combining a physical process and chemical reaction, the losses of the nitric oxide and the methyl nitrite are avoided to a great extent, the waste is changed into treasure, and resource waste and water source pollution are reduced.
Owner:安阳永金化工有限公司
Gambogicacid derivative and its preparation method and uses in pharmacy
InactiveCN1876658ASignificant cytotoxicityOrganic active ingredientsOrganic chemistryNitric oxideMedicinal chemistry
The invention discloses the preparing method and application of cambogic acid derivation. The cambogic acid derivation is made by nitric oxide donator and cambogic acid. The cambogic acid derivation has the antineoplastic action.
Owner:CHINA PHARM UNIV
Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use
The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and / or heterocyclic nitric oxide donors.
Owner:NICOX SA
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
The present invention describes novel nitrosated and / or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and / or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).
Owner:NITROMED
Novel tetraterpene derivatives and pharmaceutical use thereof
The invention relates to nitric oxide donor OA or UA derivatives formed by coupling various types of NO donors and oleanolic acid (OA) or uraolic acid (UA) which is a medicament for treating liver diseases through ester bonds or amido bonds of link groups respectively. Bioactivity researches show that some compounds have the effects of killing liver tumor cells and have an application prospect in liver cancer treatment.
Owner:王志凤
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com